Biocoat Launches HYDAK® UV

The New Version of its Original HYDAK® Coating is Designed to be Cured Using Ultraviolet (UV) Light, Allowing for Flexible Integration with industry-standard UV Coating Systems

Biocoat reports the innovative coating is built on the proven bi-laminar platform that is used in Biocoat’s existing thermal heat cure coating technology.

“Biocoat is the only hydrophilic coating provider that can provide industry-leading performance in lubricity, durability, and particulates for both UV and thermal hydrophilic coatings,” said Dr. Bob Hergenrother, Biocoat’s Senior Director of Research & Development. “Our proprietary, internally developed UV coatings are built on the same bi-laminar coating platform currently being used on leading neurovascular, cardiovascular, and ophthalmic devices in over 160 countries around the world.”

“Biocoat is at the forefront of developing coating solutions to meet the increasing demands of our customers who are developing cutting-edge medical devices.  The introduction of HYDAK® UV positions Biocoat as the premier provider of hydrophilic coatings,” said Jim Moran, Biocoat’s President, and CEO.  “By working directly with our customers to understand their needs, we’ve developed a UV coating that maximizes device performance, and we’ve designed a manufacturing process that allows them to use their current in-house equipment. In addition, Biocoat will extend our in-house coating services to offer both UV and Thermal Coating Services.”

Scott Cramer, Chairman of Biocoat added, “We believe that the future growth of Biocoat will be a direct result of simplifying the development process for our customers.  The introduction of HYDAK® UV and the launch of the Contract Coating Services Unit were strategic initiatives specifically designed to improve Biocoat’s complete service offering.”

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."